Washington Trust Bancorp, Inc. (WASH) Forms $55.70 Double Top; Palo Alto Investors Trimmed By $7.81 Million Its Amicus Therapeutics (FOLD) Holding

Washington Trust Bancorp, Inc. (WASH) formed double top with $59.60 target or 7.00% above today’s $55.70 share price. Washington Trust Bancorp, Inc. (WASH) has $959.20 million valuation. The stock increased 0.27% or $0.15 during the last trading session, reaching $55.7. About 25,068 shares traded. Washington Trust Bancorp, Inc. (NASDAQ:WASH) has risen 30.56% since January 15, 2017 and is uptrending. It has outperformed by 13.86% the S&P500.

Palo Alto Investors Llc decreased Amicus Therapeutics Inc (FOLD) stake by 6.55% reported in 2017Q3 SEC filing. Palo Alto Investors Llc sold 520,500 shares as Amicus Therapeutics Inc (FOLD)’s stock rose 23.92%. The Palo Alto Investors Llc holds 7.42 million shares with $111.90M value, down from 7.94 million last quarter. Amicus Therapeutics Inc now has $2.61 billion valuation. The stock decreased 0.95% or $0.15 during the last trading session, reaching $15.72. About 2.82 million shares traded or 24.09% up from the average. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 12.45% since January 15, 2017 and is uptrending. It has underperformed by 4.25% the S&P500.

Among 9 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Amicus Therapeutics had 20 analyst reports since August 18, 2015 according to SRatingsIntel. The rating was initiated by Bank of America on Wednesday, May 18 with “Buy”. The firm has “Neutral” rating given on Wednesday, September 16 by Chardan Capital Markets. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) has “Buy” rating given on Tuesday, March 8 by Janney Capital. Cowen & Co maintained the stock with “Buy” rating in Sunday, June 25 report. The firm earned “Overweight” rating on Tuesday, September 8 by JP Morgan. The rating was maintained by Cowen & Co with “Buy” on Tuesday, July 11. Chardan Capital Markets upgraded it to “Buy” rating and $8 target in Monday, October 5 report. Robert W. Baird maintained the stock with “Outperform” rating in Wednesday, July 12 report. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) has “Neutral” rating given on Thursday, April 14 by Robert W. Baird. The firm has “Neutral” rating given on Wednesday, March 30 by Goldman Sachs.

Analysts await Amicus Therapeutics, Inc. (NASDAQ:FOLD) to report earnings on March, 7. They expect $-0.30 earnings per share, up 6.25% or $0.02 from last year’s $-0.32 per share. After $-0.41 actual earnings per share reported by Amicus Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -26.83% EPS growth.

Since October 12, 2017, it had 0 insider purchases, and 14 insider sales for $10.19 million activity. Shares for $142,534 were sold by RAAB MICHAEL on Thursday, October 12. $147,181 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) was sold by Baird William D III on Tuesday, January 2. $117,723 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) was sold by Quimi Daphne. Another trade for 71,735 shares valued at $1.06M was made by Crowley John F on Tuesday, October 17. Shares for $71,268 were sold by Barth Jay on Thursday, October 12. On Tuesday, January 2 the insider Andrews Kurt J. sold $147,191. HAYDEN DONALD J JR sold $300,002 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Tuesday, January 2.

Palo Alto Investors Llc increased Alexion Pharmaceuticals Inc (NASDAQ:ALXN) stake by 49,400 shares to 1.08 million valued at $151.56 million in 2017Q3. It also upped Karyopharm Therapeutics Inc (NASDAQ:KPTI) stake by 31,010 shares and now owns 3.50 million shares. Epizyme Inc (NASDAQ:EPZM) was raised too.

Investors sentiment increased to 2.33 in Q3 2017. Its up 1.10, from 1.23 in 2017Q2. It is positive, as 16 investors sold FOLD shares while 32 reduced holdings. 52 funds opened positions while 60 raised stakes. 192.70 million shares or 14.18% more from 168.77 million shares in 2017Q2 were reported. Chicago Equity Prtn Limited stated it has 0.02% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Schwab Charles Invest Mgmt Incorporated holds 731,875 shares. Secor Advisors LP owns 87,251 shares or 0.13% of their US portfolio. Birchview LP has 10,000 shares. Blackrock holds 13.37 million shares. Cadian Capital Mgmt Limited Partnership holds 400,000 shares or 0.28% of its portfolio. Jpmorgan Chase And Company reported 0% stake. Raymond James And Associates has 190,564 shares for 0.01% of their portfolio. Susquehanna Intll Grp Inc Ltd Liability Partnership stated it has 0.01% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). State Common Retirement Fund reported 0% stake. Td Asset invested in 0.01% or 225,454 shares. Sectoral Asset Mgmt holds 4.69% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 2.41M shares. Victory Mngmt reported 0.08% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). The California-based Redmile Ltd has invested 8.19% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Tourbillon Prtnrs LP has 3.04 million shares.

Investors sentiment increased to 1.31 in 2017 Q3. Its up 0.15, from 1.16 in 2017Q2. It improved, as 7 investors sold Washington Trust Bancorp, Inc. shares while 28 reduced holdings. 15 funds opened positions while 31 raised stakes. 9.43 million shares or 0.20% less from 9.45 million shares in 2017Q2 were reported. California Pub Employees Retirement Sys reported 0% in Washington Trust Bancorp, Inc. (NASDAQ:WASH). Thrivent For Lutherans accumulated 61,540 shares or 0.01% of the stock. Webster Fincl Bank N A has invested 0.01% in Washington Trust Bancorp, Inc. (NASDAQ:WASH). State Street Corp has invested 0% in Washington Trust Bancorp, Inc. (NASDAQ:WASH). Envestnet Asset Mngmt reported 0% in Washington Trust Bancorp, Inc. (NASDAQ:WASH). Teton Advisors Inc invested in 60,020 shares or 0.32% of the stock. Principal Gru holds 0.06% of its portfolio in Washington Trust Bancorp, Inc. (NASDAQ:WASH) for 1.11M shares. Los Angeles And Equity Research Inc holds 0.01% or 15,790 shares in its portfolio. Tower Ltd Liability Com (Trc) has 1,370 shares for 0.01% of their portfolio. State Common Retirement Fund reported 25,460 shares or 0% of all its holdings. National Bank & Trust Of Mellon stated it has 116,215 shares. Btim Corp reported 0.13% in Washington Trust Bancorp, Inc. (NASDAQ:WASH). Washington Com invested in 487,012 shares. Commonwealth Equity invested in 20,891 shares. Great West Life Assurance Can owns 0% invested in Washington Trust Bancorp, Inc. (NASDAQ:WASH) for 1,871 shares.

Among 4 analysts covering Washington Trust Bancorp (NASDAQ:WASH), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Washington Trust Bancorp had 16 analyst reports since July 22, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Tuesday, October 20 by Compass Point. The stock has “Neutral” rating by Compass Point on Friday, November 18. The firm earned “Neutral” rating on Tuesday, September 20 by Compass Point. On Monday, October 3 the stock rating was downgraded by Keefe Bruyette & Woods to “Market Perform”. Keefe Bruyette & Woods maintained the shares of WASH in report on Thursday, December 21 with “Hold” rating. As per Tuesday, October 24, the company rating was downgraded by Compass Point. The stock of Washington Trust Bancorp, Inc. (NASDAQ:WASH) earned “Buy” rating by Compass Point on Monday, December 18. The stock of Washington Trust Bancorp, Inc. (NASDAQ:WASH) earned “Buy” rating by Compass Point on Thursday, January 26. Keefe Bruyette & Woods upgraded the stock to “Outperform” rating in Wednesday, December 30 report. The stock of Washington Trust Bancorp, Inc. (NASDAQ:WASH) earned “Hold” rating by Keefe Bruyette & Woods on Tuesday, September 26.